Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Carcinoma, Renal Cell 5Triple Negative Breast Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Waldenstrom Macroglobulinemia 1Solid Tumors 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Mesothelioma 1Melanoma 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Leukemia 1Kidney Neoplasms 1Colorectal Neoplasms 1

Interventions

Cyclophosphamide 17blinatumomab 16fludarabine 13Vincristine 11Cytarabine 10tisagenlecleucel 8pegaspargase 8nilotinib 8Methotrexate 8Inotuzumab Ozogamicin 8Clofarabine 8venetoclax 7Dexamethasone 7asparaginase erwinia chrysanthemi recombinant 6Dasatinib 6Azacitidine 5AP 1903 reagent 5aflibercept 4Mercaptopurine 4Imatinib Mesylate 4Filgrastim 4Etoposide 4Drug Therapy 4Daunorubicin 4ponatinib 3Sensitivity and Specificity 3Mitoxantrone 3Immunotherapy, Adoptive 3Granulocyte Colony-Stimulating Factor 3CPX-351 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Precursor Cell Lymphoblastic Leukemia-Lymphoma × CB-839 × Clear all
NCT02071927 2017-02-09

Study of the Glutaminase Inhibitor CB-839 in Leukemia

Calithera Biosciences, Inc

Phase 1 Completed
43 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡